Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 74

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 74
---
, for a period of not more than 30 days, for the purpose of soliciting additional proxies to approve Proposal No. 1. MIRA currently does not intend to propose postponement or adjournment at the MIRA virtual special meeting if there are sufficient votes to approve Proposal No. 1.

The affirmative vote of a majority of the votes cast virtually or by proxy at the MIRA virtual special meeting is required to approve Proposal No. 2. Abstentions and broker non-votes will have no effect on the outcome of this Proposal. It is anticipated that Proposal No. 2 will be a discretionary proposal considered routine under the rules of the Nasdaq, which generally controls the ability of brokers to vote or not vote shares held in street name on certain matters, and thus will not result in broker non-votes.

THE MIRA BOARD RECOMMENDS THAT MIRA’S STOCKHOLDERS VOTE “FOR” PROPOSAL NO. 2 TO POSTPONE OR ADJOURN THE MIRA VIRTUAL SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSAL NO. 1. THE APPROVAL OF PROPOSAL NO. 1 IS REQUIRED TO CONSUMMATE THE MERGER.

| 38 |

<div align='center'>DESCRIPTION OF SKNY’S BUSINESS</div>

Overview

SKNY Pharmaceuticals, Inc. (“SKNY”) is a preclinical-stage company developing SKNY-1, a novel oral therapeutic designed to modulate cannabinoid receptors CB1 and CB2, as well as selectively inhibit monoamine oxidase B (MAO-B), an enzyme involved in dopamine metabolism and addiction regulation. SKNY-1 is being developed for two lead indications: weight loss and nicotine dependence. SKNY holds exclusive rights to SKNY-1 in the United States, Canada, and Mexico. Despite existing treatments in both therapeutic areas, SKNY-1 is believed to offer the potential for improved efficacy with a favorable safety profile, making it a promising candidate for both the weight loss and nicotine dependence markets.

Obesity and smoking share pharmacological and physiological connections that intertwine through neurotransmitter systems, metabolic pathways, and behavioral mechanisms. These links influence how each condition affects the other, smoking can suppress weight gain, while quitting often swaps nicotine craving for food craving, as both hit dopamine pathways. (Source: Cell Press, Neuron Review)

SKNY’sresearch indicates that SKNY-1